Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTHNASDAQ:IOVANASDAQ:UPBNYSE:VCXB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$19.12+4.0%$18.85$13.37▼$32.27$606.22M1.38264,856 shs101,602 shsIOVAIovance Biotherapeutics$1.75+0.2%$2.15$1.64▼$12.51$584.39M0.859.02 million shs4.64 million shsUPBUpstream Bio$11.20+0.6%$9.99$5.14▼$29.46$602.49MN/A352,911 shs212,087 shsVCXB10X Capital Venture Acquisition Corp. III$11.07$11.05$10.48▼$12.99$146.01M0.0743,760 shs16,992 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics0.00%+8.42%+2.93%+18.58%-27.73%IOVAIovance Biotherapeutics0.00%+3.79%-2.56%-41.53%-76.27%UPBUpstream Bio0.00%+2.47%+3.42%+83.61%+1,119,999,900.00%VCXB10X Capital Venture Acquisition Corp. III0.00%0.00%0.00%0.00%+0.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNTHDianthus Therapeutics1.6093 of 5 stars3.60.00.00.03.30.80.0IOVAIovance Biotherapeutics4.706 of 5 stars4.31.00.04.21.74.21.3UPBUpstream BioN/AN/AN/AN/AN/AN/AN/AN/AVCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 3.13Buy$53.00177.27% UpsideIOVAIovance Biotherapeutics 2.50Moderate Buy$12.22596.82% UpsideUPBUpstream Bio 3.00Buy$56.50404.46% UpsideVCXB10X Capital Venture Acquisition Corp. III 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VCXB, IOVA, UPB, and DNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025DNTHDianthus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/16/2025IOVAIovance BiotherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$17.00 ➝ $2.005/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/12/2025IOVAIovance BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $8.005/12/2025IOVAIovance BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $10.005/12/2025IOVAIovance BiotherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/12/2025IOVAIovance BiotherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/9/2025IOVAIovance BiotherapeuticsBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/9/2025IOVAIovance BiotherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/9/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $25.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$6.52M94.23N/AN/A$11.91 per share1.60IOVAIovance Biotherapeutics$212.68M2.75N/AN/A$2.33 per share0.75UPBUpstream Bio$2.37M254.20N/AN/A$8.77 per share1.28VCXB10X Capital Venture Acquisition Corp. IIIN/AN/A$0.06 per share176.88($1.49) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.24N/AN/AN/A-176.49%-49.71%-39.18%8/6/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/AN/AN/AN/A8/5/2025 (Estimated)VCXB10X Capital Venture Acquisition Corp. III$700KN/A0.00∞N/AN/AN/AN/AN/ALatest VCXB, IOVA, UPB, and DNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million5/6/2025Q1 2025UPBUpstream Bio-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/AVCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A15.9815.99IOVAIovance BiotherapeuticsN/A4.183.64UPBUpstream BioN/A47.4347.43VCXB10X Capital Venture Acquisition Corp. IIIN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%IOVAIovance Biotherapeutics77.03%UPBUpstream BioN/AVCXB10X Capital Venture Acquisition Corp. III13.25%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics8.15%IOVAIovance Biotherapeutics10.30%UPBUpstream Bio13.56%VCXB10X Capital Venture Acquisition Corp. III82.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8032.16 million29.54 millionOptionableIOVAIovance Biotherapeutics500333.93 million299.54 millionOptionableUPBUpstream Bio3853.79 million46.50 millionN/AVCXB10X Capital Venture Acquisition Corp. III413.19 million2.31 millionNot OptionableVCXB, IOVA, UPB, and DNTH HeadlinesRecent News About These Companies10X Capital Venture Acquisition Corp. III Receives NYSE Notice Regarding Late Form 10-K FilingApril 23, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingVCXB, IOVA, UPB, and DNTH Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$19.11 +0.74 (+4.00%) As of 07/3/2025 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Iovance Biotherapeutics NASDAQ:IOVA$1.75 +0.00 (+0.23%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.76 +0.00 (+0.11%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Upstream Bio NASDAQ:UPB$11.20 +0.07 (+0.63%) As of 07/3/2025 01:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.10X Capital Venture Acquisition Corp. III NYSE:VCXB10X Capital Venture Acquisition Corp. III does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to identify business opportunities in the field of consumer internet, e-commerce, software, healthcare, transportation/mobility, financial services, artificial intelligence, automation, data science, and Software-as-a-Service. The company was incorporated in 2021 and is based in New York, New York. 10X Capital Venture Acquisition Corp. III operates as a subsidiary of 10X Capital SPAC Sponsor III LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
